CGC · Canopy Growth Corporation · Stock research

Current Thesis

Since the 2026-07-26 note the narrative leg has changed hands. The federal rescheduling binary that gave CGC its beta is still parked — the DEA hearing closed 2026-07-15, post-hearing briefs are due 2026-08-17, and Chief ALJ Derek C. Julius set no timeline for his recommendation, which trade coverage now places in late 2026 with appellate risk into 2027 (Marijuana Moment, 2026-07; The Marijuana Herald, 2026-07). What actually re-priced the stock was operational: the 2026-08-07 Q1 FY2027 report showed net revenue of C$81.2M, +13% YoY, adjusted EBITDA loss of C$3.2M (a 59% YoY improvement), and adjusted gross margin of 31% against 25% a year earlier. Shares closed $1.02 on 2026-08-14 versus $0.8886 on 2026-07-24. An investor buying here is buying a Canadian medical/international cannabis operator approaching adjusted-EBITDA breakeven, with a free option on a US adult-use reschedule that no longer has a date attached. The share count is the standing counterweight: 449.3M outstanding at 2026-06-30 (423.0M common plus 26.3M exchangeable).

Bullish and bearish views on Canopy Growth Corporation

The model's bull view on Canopy Growth Corporation (CGC), in brief: Q1 FY2027 (2026-08-07): net revenue C$81.2M, +13% YoY, with growth in every segment — Canada medical C$25.8M (+22%), Canada adult-use C$29.7M (+10%), international cannabis C$9.6M (+10%), Storz & Bickel C$16.1M (+6%). The bear view: The reschedule pays someone else. 280E relief accrues to US plant-touching operators — Trulieve, Green Thumb, Curaleaf. Canopy is a Canadian LP whose US exposure runs indirectly through Canopy USA; a favourable rule reaches CGC's P&L through sentiment and the Canopy USA… Both cases follow in full.

Bull Case

• Q1 FY2027 (2026-08-07): net revenue C$81.2M, +13% YoY, with growth in every segment — Canada medical C$25.8M (+22%), Canada adult-use C$29.7M (+10%), international cannabis C$9.6M (+10%), Storz & Bickel C$16.1M (+6%). Cannabis segment revenue C$65.1M, +14%.
• Loss curve bending: adjusted EBITDA loss narrowed to C$3.2M from C$7.9M-equivalent a year earlier (reported as a 59% improvement), adjusted gross margin 31% vs 25%, and net loss 68% lower YoY. Management said it "anticipates further improvements… especially in the second half of fiscal 2027" without publishing a numeric target.
• The export channel stayed open: on 2026-08-14 the Kincardine, Ontario cultivation facility received renewed EU Good Manufacturing Practice certification, preserving the route for Canadian-grown flower into European medical markets — the same channel that produced the +10% international line in Q1.
• Liquidity is not the near-term question: C$336.6M cash and equivalents plus C$5.1M restricted short-term investments at 2026-06-30, against total debt of C$240.2M (C$28.8M current, C$211.4M long-term). FY2026 (reported 2026-06-15) closed in a +$131.3M net cash position after the January 2026 recapitalization.
• The policy record leaned constructive: through the 2026-06-29 → 2026-07-15 hearing the DEA argued as the Schedule III proponent while seven designated opponents cross-examined the government's own witnesses. The April 2026 order already moved FDA-approved products and state-licensed medical marijuana out of Schedule I (Federal Register, 2026-04-28); only the adult-use leg is open.

Bear Case

• The reschedule pays someone else. 280E relief accrues to US plant-touching operators — Trulieve, Green Thumb, Curaleaf. Canopy is a Canadian LP whose US exposure runs indirectly through Canopy USA; a favourable rule reaches CGC's P&L through sentiment and the Canopy USA structure, not through a tax line.
• Dilution has not stopped. 449.3M shares outstanding at 2026-06-30 (423.0M common + 26.3M exchangeable), against ~422.15M common reported at 2026-07-24 and roughly 378M in June 2026 — a count that has been lifted repeatedly by ATM issuance and stock-funded M&A. Equity issued into strength is the mechanism by which good headlines get absorbed.
• Cash is still leaving. Free cash outflow was C$25.7M in Q1 FY2027. Adjusted EBITDA loss of C$3.2M is a much smaller number than the cash burn it sits above.
• The catalyst is a filing, not a decision. 2026-08-17 produces briefs of up to 50 pages, after which the ALJ recommendation goes to the DEA Administrator, whose final rule is widely expected to be challenged. Nothing on 2026-08-17 resolves the schedule.
• The Q1 beat was thin in absolute terms. In USD reporting terms the print was sales of $58.63M against a $58.52M consensus and EPS of $(0.02) versus $(0.04) — a beat measured in cents on a sub-$1.10 stock, arriving after the shares had already lost 46.9% from the 52-week high of $1.92.

Setup & Price Structure

Last completed daily close $1.02 (2026-08-14). That is -46.9% from the $1.92 52-week high and sits above the $0.8435 52-week low recorded before the 2026-07-24 reference close of $0.8886. The three-month return is -1.9% while RSI(14) reads 66.8 — the recent strength is a recovery inside a flat three-month range rather than a trend that has already broken out. The $1.00 handle is the nearest structural line: it separates the post-Q1 advance from the July retest zone.

The narrative is maturing. The rescheduling narrative itself is late-cycle and thinly bid — the hearing that was supposed to resolve it ended 2026-07-15 with a brief schedule and no verdict, and the stock is still 46.9% below its 52-week high. What is working is the second, quieter leg: two dated operating headlines inside eight sessions (2026-08-07 earnings, 2026-08-14 EU GMP renewal) took the stock back over $1.00. That leg is known to holders and moderately flowed, not newly discovered — the equity has been publicly covered on this frame since 2026-04-23.

Crowding and positioning observables, stated as observables: eight-analyst consensus was Hold with a $1.23 price target as of 2026-07-24, leaving the 2026-08-14 close inside the target band rather than below it; short interest was approximately 6% of float (MarketBeat, May 2026, and stale by three months) — a level that does not describe a squeeze setup; the share count rose from roughly 378M in June 2026 to 422.15M common at 2026-07-24, with 449.3M total including exchangeables at 2026-06-30, which is issuance into every rally this name has produced; RSI(14) at 66.8 with price -46.9% from the high is strength measured against a low reference, not a momentum extension; and there is no company earnings date inside the next 30 days to force a re-rate either way.

Catalyst Calendar (next 30 days)

• 2026-08-18 → 2026-09-15 — Open docket window. Any scheduling order, recommendation, or DEA statement would land here unannounced; no date is calendared, and coverage points to a recommendation in late 2026 (Marijuana Moment, 2026-07).

Elapsed catalysts

• 2026-08-17 — Post-hearing brief deadline in the DEA marijuana rescheduling proceeding (order of Chief ALJ Derek C. Julius, 2026-07-16). Submissions up to 50 pages; no closing arguments were heard in person, so the briefs are the last substantive filings before the recommendation. (passed 9d ago)
• ~2026-11 (est.) — Q2 FY2027 print, outside this window. It is the next scheduled test of the "further improvements in the second half of fiscal 2027" language from 2026-08-07. (passed 19d ago)

What Would Change Our Mind

The entire thesis-relevant change since the last note is the post-2026-08-07 advance off the July lows. Give that back and the position of the name is exactly where it was on 2026-07-24, with a larger share count. Specifically: a weekly close below $0.90 hands back the post-Q1 move and re-exposes the $0.8435 52-week low, which would date the operating leg as a two-week sentiment bounce rather than a re-rate.

Three further conditions would break the frame independently of price. First, 2026-08-17 passing with a docket entry that pushes the ALJ recommendation openly into 2027 — that converts the policy option from undated to dead-for-the-year and leaves only the operating story. Second, a new ATM tranche or stock-funded acquisition lifting the count above the 449.3M disclosed at 2026-06-30 without a matching revenue step; the 2026-08-07 growth rates are per-share-neutral at best if the denominator keeps expanding. Third, a Q2 FY2027 report that fails to narrow the C$25.7M quarterly free cash outflow, which would mean the adjusted-EBITDA improvement is not reaching cash. On the other side, a favourable ALJ recommendation would flip the frame — but the cleaner exposure to 280E relief is the US MSO complex, not a Canadian LP.

Correlation Notes

• Moves with the US cannabis policy complex on headline days: TCNNF, GTBIF, CURLF and the MSOS basket. CGC typically trades the sentiment beta of that basket while the tax economics accrue to the plant-touching US names.
• Reports in Canadian dollars while trading on a US exchange; the 2026-08-07 print reads C$81.2M net revenue and roughly US$58.6M in the consensus comparison. CAD/USD moves show up in reported growth rates for US-based screens.
• International revenue is levered to EU medical import regimes — the 2026-08-14 Kincardine EU GMP renewal is a licence-condition dependency, not a demand signal.
• Sub-$1.10 float with ~6% short interest (MarketBeat, May 2026): headline moves are driven by issuance-absorbed retail flow rather than short covering, which is why rallies here have historically met supply.